Phase I Study of ABT-888 (veliparib) in Combination With Cisplatin and Vinorelbine for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer
Full study details on clinicaltrials.gov
Name of PARP Inhibitor used in study:
- Patients with recurrent and/or metastatic triple negative breast cancer or BRCA1 or BRCA2 mutation and recurrent and/or metastatic breast cancer
- Subjects must have measurable disease, defined as at least one lesion that can be measured in at least one dimension; this includes measurable (bi-dimensional) chest wall disease and/or cutaneous metastatic lesions at least 10 mm
Type of study:
Phase I study
Patients receive oral ABT-888 twice daily on days 1-14 (days 0-13 of course 1 only). Patients also receive cisplatin IV and vinorelbine IV on days 1 and 8. Treatment repeats every 21 days for 6- 10 courses in the absence of disease progression or unacceptable toxicity. Treatment with ABT-888 alone may continue in the absence of disease progression or unacceptable toxicity.
Fred Hutchinson Cancer Research Center/University of Washington Cancer
Seattle, Washington, 98109
Contact: Seattle Cancer Care Alliance 800-804-8824
Principal Investigator: Eve Th Rodler
Page updated 03/21/11
Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.
This site has been made possible by a generous grant from Morphotek.